Recent Finacing
Recent Raise
Halda Therapeutics develops RIPTAC heterobifunctional "hold-and-kill" therapeutics, advancing HLD-0915 into Phase 1 for mCRPC and a second RIPTAC program toward clinical development for metastatic breast cancer.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Halda Therapeutics.
